On November 9, Centrus saw an Intraday Rise of 8.41% in Regular Trading, with shares trading at $113.31 and turnover reaching $22.8818 million.
The most direct catalyst cited by recent market updates was a continuation of sentiment recovery after broker upgrades announced earlier in the week.
Recent rating actions showed Roth Capital upgrading Centrus to Buy from Neutral with a $115 price target, while Canaccord Genuity also upgraded the stock to Buy. This came after the company reported third-quarter adjusted EPS of negative $0.49 on revenue of $55.5 million, both below expectations. With earnings-related pressure having already weighed on the shares, the shift in analyst stance appears to have helped drive the rebound, alongside strength across uranium-related names in the broader fuels space.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments